A phase 3 trial involving nearly 25,000 older adults across 17 countries found that a single dose of the RSVPreF3 OA vaccine ...

ACIP is recommending that adults aged 50 to 59 years who are at increased risk for severe RSV disease receive a single dose of an RSV vaccine.

RSV, a common virus that triggers lung infections, can be especially dangerous for older people and lead to bronchiolitis and pneumonia. According to the Centers for Disease Control and Protection ...

"Nirsevimab is highly effective in preventing RSV-related outcomes in infants, with a pooled real-world effectiveness of 83 ...

Vulnerable Australians aged 50-59 will be able to receive a vaccine for respiratory syncytial virus (RSV).

Young children with chronic conditions are more likely to be hospitalized for respiratory syncytial virus (RSV) than healthy children, according to a new study.

In addition to the RSV vaccine vote ... that people who have undergone lung transplantation, or who have heart failure, chronic obstructive pulmonary disease, chronic kidney disease, or severe ...

Monoclonal antibody nirsevimab provides strong real-world protection against severe RSV in infants, suggests meta-analysis ...

A new global study led by GlaxoSmithKline has found that a single dose of the RSV vaccine Arexvy (RSVPreF3 OA) offers strong ...

Hospitalisation rates in 50-64-year-olds with chronic obstructive pulmonary disease (COPD ... to completely recover from RSV, likely because she had an existing lung condition – excessive ...